For the Inventor, By the Inventor

Enter assignee name

Cranbury, NJ, United States of America

Amicus Therapeutics, Inc.

USPTO Granted Patents = 161

% Expired Patents = 4.3

CIPO Patents = 12

EPO Patents = 75

Trademarks = 17

Forward Citations = 2,002

Loading Chart...

Loading Chart...

58 inventors (with patents filed for the assignee):

Jeff Castelli (58 out of 59 patents)

Elfrida Benjamin (56 out of 56 patents)

Hung V Do (33 out of 33 patents)

4. Robert E Boyd (20 out of 33 patents)

5. Russell Gotschall (17 out of 17 patents)

6. Brandon Alan Wustman (15 out of 19 patents)

7. David J Lockhart (15 out of 61 patents)

8. Richie Khanna (14 out of 14 patents)

9. Gary Lee (14 out of 15 patents)

10. Kenneth Valenzano (13 out of 13 patents)

11. Philip J Rybczynski (12 out of 32 patents)

12. Kamlesh A Sheth (12 out of 12 patents)

13. John R Flanagan (11 out of 139 patents)

14. Sergey Tesler (8 out of 8 patents)

15. John Crowley (6 out of 6 patents)

Core Competencies:

Lysosomal Storage Diseases

Fabry Disease

Pompe Disease

Pharmacological Chaperones

Acid Alpha-Glucosidase

Recombinant Proteins

Gene Therapy Constructs

Degenerative Disorders

Migalastat

Disulfide Bond Stabilized Polypeptides

Alzheimer's Disease

161 patents: Sort by Forward Citations

1. 12686859 - Method For Selection Of High M6P Recombinant Proteins (2026-07-21),

2. 12622952 - FORMULATIONS COMPRISING RECOMBINANT ACID ALPHA-GLUCOSIDASE (2026-05-12),

3. 12599595 - Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones (2026-04-14),

4. 12552736 - Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders (2026-02-17),

5. 12419937 - High concentration alpha-glucosidase compositions for the treatment of Pompe disease (2025-09-23),

6. 12414985 - Augmented acid alpha-glucosidase for the treatment of Pompe disease (2025-09-16),

7. 12414944 - Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene (2025-09-16),

8. D1087752 - Drug package (2025-08-12),

9. D1082532 - Drug package (2025-07-08),

10. 12280042 - Methods of treating fabry patients having renal impairment (2025-04-21),

11. 12275703 - Highly purified batches of pharmaceutical grade migalastat and methods of producing the same (2025-04-14),

12. 12246062 - Recombinant human acid alpha-glucosidase (2025-03-11),

13. 12109205 - Methods of treating Fabry patients having renal impairment (2024-10-08),

14. 12070453 - Treatment of Fabry disease in ERT-naïve and ERT-experienced patients (2024-08-27),

15. 12064485 - Disulfide bond stabilized polypeptide compositions and methods of use (2024-08-20),

Company Overview

Amicus Therapeutics, Inc. is a biopharmaceutical company based in Cranbury, NJ, specializing in the development of therapies for lysosomal storage diseases. The company focuses on innovative treatments for conditions such as Fabry disease and Pompe disease, utilizing core technologies like pharmacological chaperones and recombinant proteins. Amicus is dedicated to advancing gene therapy constructs and addressing degenerative disorders, aiming to improve the lives of patients affected by these challenging diseases.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

161 Patents

#2 in Cranbury, NJ

#114 in New Jersey

#2,464 in US

#5,117 in the World

Cranbury, NJ, United States of America

Amicus Therapeutics, Inc.

Forward Citations = 2,002

58 inventors:

Jeff Castelli (58 out of 59 patents)

Elfrida Benjamin (56 out of 56 patents)

Hung V Do (33 out of 33 patents)

4. Robert E Boyd (20 out of 33 patents)

5. Russell Gotschall (17 out of 17 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Amicus Therapeutics, Inc.. Retrieved from https://idiyas.com/company/amicus-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…